Sarepta sets wholesale acquisition cost for ELEVIDYS at $3.2 million

Sarepta Therapeutics, Inc.

Wholesale acquisition cost (gross price) of gene therapy ELEVIDYS set at $3.2 million.
Indicated for ambulatory pediatric patients aged 4-5 years with DMD gene mutation.
Price disclosed during investor webcast on June 22, 2023.
NASDAQ ticker: SRPT.

item 7.01 item 9.01

Sarepta Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-029438

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.